CY1123900T1 - Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης - Google Patents

Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης

Info

Publication number
CY1123900T1
CY1123900T1 CY20211100151T CY211100151T CY1123900T1 CY 1123900 T1 CY1123900 T1 CY 1123900T1 CY 20211100151 T CY20211100151 T CY 20211100151T CY 211100151 T CY211100151 T CY 211100151T CY 1123900 T1 CY1123900 T1 CY 1123900T1
Authority
CY
Cyprus
Prior art keywords
mammal
treatment
pulmonary hypertension
arterial hypertension
pulmonary arterial
Prior art date
Application number
CY20211100151T
Other languages
Greek (el)
English (en)
Inventor
Edda SPIEKERKOETTER
Marlene Rabinovitch
Philip A. Beachy
David Solow-Cordero
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of CY1123900T1 publication Critical patent/CY1123900T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20211100151T 2011-05-02 2021-02-23 Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης CY1123900T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02
PCT/US2012/035793 WO2012151153A1 (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CY1123900T1 true CY1123900T1 (el) 2022-05-27

Family

ID=47108011

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100151T CY1123900T1 (el) 2011-05-02 2021-02-23 Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP4279130A3 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK2704711T3 (enExample)
ES (2) ES2856173T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT3821891T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
MX2017014301A (es) * 2015-05-08 2018-03-23 Vivus Inc Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
CN108070566A (zh) * 2015-08-05 2018-05-25 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
EP3773571A1 (en) 2018-03-28 2021-02-17 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
FR2936060B1 (fr) * 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Also Published As

Publication number Publication date
SMT202100085T1 (it) 2021-05-07
CA2834368C (en) 2020-02-18
ES2856173T3 (es) 2021-09-27
WO2012151153A1 (en) 2012-11-08
EP4279130A2 (en) 2023-11-22
LT2704711T (lt) 2021-04-26
EP2704711A4 (en) 2014-11-19
JP2014513121A (ja) 2014-05-29
HUE053229T2 (hu) 2021-06-28
US9474745B2 (en) 2016-10-25
EP3821891A1 (en) 2021-05-19
DK2704711T3 (da) 2021-02-22
CA2834368A1 (en) 2012-11-08
HRP20210245T1 (hr) 2021-04-02
AU2012250974B2 (en) 2017-05-04
US20170007585A1 (en) 2017-01-12
ZA201307905B (en) 2015-05-27
US20180185340A1 (en) 2018-07-05
US20220184042A1 (en) 2022-06-16
EP3821891B1 (en) 2023-06-07
JP6177765B2 (ja) 2017-08-09
US20140135358A1 (en) 2014-05-15
ES2954905T3 (es) 2023-11-27
US12521379B2 (en) 2026-01-13
SI2704711T1 (sl) 2021-04-30
PL2704711T3 (pl) 2021-07-05
US20230404982A1 (en) 2023-12-21
AU2017210583A1 (en) 2017-08-24
DK3821891T3 (da) 2023-09-04
FI3821891T3 (fi) 2023-08-24
AU2012250974A1 (en) 2013-11-14
AU2017210583B2 (en) 2019-02-07
PT3821891T (pt) 2023-08-31
EP2704711B1 (en) 2020-12-02
US20190091208A1 (en) 2019-03-28
AU2012250974B9 (en) 2017-05-18
RS61480B1 (sr) 2021-03-31
EP2704711A1 (en) 2014-03-12
EP4279130A3 (en) 2024-02-21
PT2704711T (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201400565A1 (ru) Молекулы антител, имеющие специфичность в отношении ох40 человека
IL237021B (en) Pharmaceutical composition for treatment of pulmonary arterial hypertension with mesenchymal stem cells
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
CO6561789A2 (es) Método de tratamiento
LT2704711T (lt) Fk506 panaudojimas plaučių arterinei hipertenzijai gydyti
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
RU2011126854A (ru) Способ моделирования хронической сердечной недостаточности в эксперименте
RU2011119393A (ru) Способ лечения пациентов с хроническим геммороем путем латексного лигирования геморроидального узла
UA48652U (ru) Способ оценки эффективности лечения больных ишемической болезнью сердца со стенокардией и артериальной гипертензией спираприлом
UA68459U (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
UA83094U (ru) Способ коррекции эндотелиальной дисфункции и профилактики поражений артерий у больных гипертонической болезнью
UA59716U (ru) Способ лечения ишемической болезни сердца у женщин с сопутствующей ренопаренхиматозной артериальной гипертензией
UA75914U (uk) Спосіб підготовки дистального русла для артеріальної реконструкції при хронічній критичній ішемії нижньої кінцівки
UA68460U (ru) Способ оценки эффективности лечения s-атенололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
UA70143U (uk) Спосіб оцінки функціонального стану мікроциркуляторної системи
UA46778U (ru) Способ оценки эффективности лечения больных ишемической болезнью сердца со стенокардией и артериальной гипертензией бисопрололом
RU2013151036A (ru) Интраоперационный способ купирования спазма коронарных артерий в кардиохирургии
PL396438A1 (pl) Wykorzystanie melatoniny do wytwarzania leku do nowego zastosowania
RU2011117860A (ru) Способ лечения больных красным плоским лишаем слизистой оболочки рта
UA72092U (ru) Способ оценки эффективности лечения розувастатином больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу